MedTrace Logo

Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

NCT06947382 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1066

Last updated 2025-04-27

No results posted yet for this study

Summary

This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.

Conditions

  • Pancreatic Cancer Stage I
  • Pancreatic Cancer Stage II
  • Cancer Diagnosis
  • PDAC - Pancreatic Ductal Adenocarcinoma

Sponsors & Collaborators

  • Immunovia, Inc.

    lead INDUSTRY

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2024-12-09
Completion
2025-01-06

Countries

  • United States
  • Canada
  • Italy
  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06947382 on ClinicalTrials.gov